A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
Recruiting now
Conditions studied: Primary Hypercholesterolemia, Mixed Dyslipidemia
In brief
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
Key facts
- Study ID
- NCT06314919
- Run by
- Boryung Pharmaceutical Co., Ltd
- People needed
- 8606
- Starts
- 2024-03-15
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2025-09-12
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia
- Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe
You may not qualify if…
- Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment
- Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe
- Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.
Where it is running
- Ewha Womans University Seoul Hospital — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.